Since 2005, the American Psychiatric Association has recommended BLT as a treatment option for patients with major depressive ...
Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when ...
The global major depressive disorder (MDD) treatment market is expected to experience steady growth, projected to develop at ...
Bright light therapy, a standard treatment for seasonal depression, may also help people who experience depression year-round ...
TORONTO--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough ...
Twelve months after two 16 mg doses of the drug, called CYB003, seven patients saw their scores improve on the ...
Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders
This new formulation, which targets both the serotonin 5-HT4 receptor (5-HT4R) and the NMDA receptor (NMDAR), has shown potential as a treatment for major depressive disorder (MDD), and other severe ...
Patients with non-seasonal depression who were treated with bright light therapy reported a 40% remission rate, according to a recent study.
Expert at UAB sheds light on the mental health phenomenon that casts a shadow over the colder months. As the days grow ...
PharmacoEconomics: “Economic Burden of Treatment-Resistant Depression among Adults with Chronic Non-Cancer Pain Conditions and Major Depressive Disorder in the US.” GoodTherapy ...
(RTTNews) - Silo Pharma, Inc. (SILO), Monday announced positive results from a pre-clinical study of SPC-15 showing potential for the treatment of major depressive disorder, and other severe ...
Cybin (NYSE American: CYBN) (NEO: CYBN) shared promising 12-month efficacy data from its Phase 2 study of CYB003, a proprietary deuterated ps ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback